276 related articles for article (PubMed ID: 26216943)
1. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
Pépin D; Sosulski A; Zhang L; Wang D; Vathipadiekal V; Hendren K; Coletti CM; Yu A; Castro CM; Birrer MJ; Gao G; Donahoe PK
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4418-27. PubMed ID: 26216943
[TBL] [Abstract][Full Text] [Related]
2. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
3. The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia.
Song JY; Chen KY; Kim SY; Kim MR; Ryu KS; Cha JH; Kang CS; MacLaughlin DT; Kim JH
Int J Oncol; 2009 Jun; 34(6):1583-91. PubMed ID: 19424576
[TBL] [Abstract][Full Text] [Related]
4. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Pieretti-Vanmarcke R; Donahoe PK; Pearsall LA; Dinulescu DM; Connolly DC; Halpern EF; Seiden MV; MacLaughlin DT
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17426-31. PubMed ID: 17088539
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
6. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
7. Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.
Basal E; Ayeni T; Zhang Q; Langstraat C; Donahoe PK; Pepin D; Yin X; Leof E; Cliby W
Curr Mol Med; 2016; 16(3):222-31. PubMed ID: 26917267
[TBL] [Abstract][Full Text] [Related]
8. Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival.
Chauvin M; Garambois V; Choblet S; Colombo PE; Chentouf M; Gros L; De Brauwere DP; Duonor-Cerutti M; Dumas K; Robert B; Jarlier M; Martineau P; Navarro-Teulon I; Pépin D; Chardès T; Pèlegrin A
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34013359
[TBL] [Abstract][Full Text] [Related]
9. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I
MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316
[TBL] [Abstract][Full Text] [Related]
10. An update on Mullerian-inhibiting substance: its potential application against ovarian cancer.
Wong RR; Worley MJ; Chung TK; Wong YF
Endocr Relat Cancer; 2014 Jun; 21(3):R227-33. PubMed ID: 24623744
[TBL] [Abstract][Full Text] [Related]
11. Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.
Hwang SJ; Suh MJ; Yoon JH; Kim MR; Ryu KS; Nam SW; Donahoe PK; Maclaughlin DT; Kim JH
Int J Oncol; 2011 Oct; 39(4):811-20. PubMed ID: 21573503
[TBL] [Abstract][Full Text] [Related]
12. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.
Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT
Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896
[TBL] [Abstract][Full Text] [Related]
13. c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction.
Renlund N; Pieretti-Vanmarcke R; O'Neill FH; Zhang L; Donahoe PK; Teixeira J
Endocrinology; 2008 Jan; 149(1):108-15. PubMed ID: 17947357
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.
Szotek PP; Pieretti-Vanmarcke R; Masiakos PT; Dinulescu DM; Connolly D; Foster R; Dombkowski D; Preffer F; Maclaughlin DT; Donahoe PK
Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11154-9. PubMed ID: 16849428
[TBL] [Abstract][Full Text] [Related]
15. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA
Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723
[TBL] [Abstract][Full Text] [Related]
16. Anti-Proliferative and Apoptotic Activities of Müllerian Inhibiting Substance Combined with Calcitriol in Ovarian Cancer Cell Lines.
Jung YS; Kim HJ; Seo SK; Choi YS; Nam EJ; Kim S; Kim SW; Han HD; Kim JW; Kim YT
Yonsei Med J; 2016 Jan; 57(1):33-40. PubMed ID: 26632380
[TBL] [Abstract][Full Text] [Related]
17. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.
Isayeva T; Ren C; Ponnazhagan S
Clin Cancer Res; 2005 Feb; 11(3):1342-7. PubMed ID: 15709207
[TBL] [Abstract][Full Text] [Related]
18. Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.
Chang HL; Pieretti-Vanmarcke R; Nicolaou F; Li X; Wei X; MacLaughlin DT; Donahoe PK
Gynecol Oncol; 2011 Jan; 120(1):128-34. PubMed ID: 21056908
[TBL] [Abstract][Full Text] [Related]
19. AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy.
Kano M; Sosulski AE; Zhang L; Saatcioglu HD; Wang D; Nagykery N; Sabatini ME; Gao G; Donahoe PK; Pépin D
Proc Natl Acad Sci U S A; 2017 Feb; 114(9):E1688-E1697. PubMed ID: 28137855
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a Müllerian-inhibiting substance autocrine/paracrine system in adult human endometrium.
Wang J; Dicken C; Lustbader JW; Tortoriello DV
Fertil Steril; 2009 Apr; 91(4):1195-203. PubMed ID: 18328480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
